Multicenter retrospective observational study for hepatitis B virus reactivation-related liver complications in HBsAg-positive patients with diffuse large B-cell lymphoma following rituximab-containing chemotherapy

Not Applicable

• Conditions: Diffuse large B-cell lymphoma

• Registration Number: JPRN-UMIN000025574
• Lead Sponsor: Department of Hematology, National Cancer Center Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-09
• Study Completion: 2017-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria for HBsAg-positive group: 1) Seropositive for hepatitis C virus 2) Seropositive for human immunodeficiency virus 3) Alanine transaminase level of 100 U/L or more at baseline 4) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 5) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 6) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 7) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma Exclusion criteria for HBsAg-negative group: 1) Seropositive for HBsAg before or at diagnosis of DLBCL 2) Seropositive for hepatitis C virus 3) Seropositive for human immunodeficiency virus 4) Alanine transaminase level of 100 U/L or more at baseline 5) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 6) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 7) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 8) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma

Study & Design

• Study Type: Observational
• Study Design: Not specified